Clinical Trial Update: Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is evaluating switching coronary artery disease patients from dual antiplatelet therapy to monotherapy with a potent P2Y12 inhibitor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• PRASUGREL (prasugrel)
• TICAGRELOR (ticagrelor)

Snippet

Sponsor: University of Florida | Conditions: Coronary Artery Disease | Phase 4 | Status: RECRUITING